Pharmacologic treatments effective in both generalized anxiety disorder and major depressive disorder: Clinical and theoretical implications

Canadian Journal of Psychiatry

Volumn 43, Issue 7, 1998, Pages 722-730

  Casacalenda, Nicola ^a   Boulenger, Jean Philipe ^b  

^a MCGILL UNIVERSITY   (Canada)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

Antianxiety agents; Antidepressants; Anxiety disorders; Benzodiazepines; Buspirone; Depressive disorders; Generalized anxiety disorder

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; GEPIRONE; IMIPRAMINE; PAROXETINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY NEUROSIS; ARTICLE; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; HUMAN; INSOMNIA; PANIC; PSYCHOMOTOR RETARDATION; SOMATIZATION;

EID: 0031724703     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674379804300707     Document Type: Article

References (93)

1. Andrews G, Stewart G, Morris-Yates A, Holt P, Henderson AS. Evidence for a general neurotic syndrome. Br J Psychiatry 1990;157:6-12.
2. Klein DF. Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia 1964;5:397-408.
3. Klein DF. Importance of psychiatric diagnosis in prediction of clinical drug effects. Arch Gen Psychiatry 1967;16:118-26.
4. Tyrer P, Seivewright N, Murphy S, Ferguson B, Kingdon D, Barczak P, and others. The Nottingham study of neurotic disorder: comparison of drug and psychological treatments. Lancet 1988;2:235-40.
5. Tyrer P, Seivewright N, Ferguson B, Murphy S, Johnson AL. The Nottingham study of neurotic disorder: effect of personality status on response to drug treatment, cognitive therapy, and self-help over two years. Br J Psychiatry 1993;162:219-26.
6. Andrews G, Stewart G, Allen R, Henderson AS. The genetics of six neurotic disorders: a twin study. J Affect Dis 1990;19:23-9.
7. Watson D, Clark LA. Negative affectivity: the disposition to experience negative emotional states. Psychol Bull 1984;96:465-90.
8. Clark LA, Watson D. General affective dispositions and their importance in physical and psychological health. In: Handbook of social and clinical psychology: the health perspective. CR Snyder, DR Forsyth, editors. New York: Pergamon Press; 1991. p 221-45.
9. Jardine R, Martin NG, Henderson AS. Genetic covariation between neuroticism and the symptoms of anxiety and depression. Genetic Epidemiol 1984;1:89-107.
10. Kendler KS, Heath AC, Martin NG, Eaves LJ. Symptoms of anxiety and symptoms of depression: same genes, different environments? Arch Gen Psychiatry 1987;44:451-7.
11. Pedersen NL, Plomin R, McClearn GE, Friberg L. Neuroticism, extraversion, and related traits in adult twins reared apart and reared together. J Pers Soc Psychol 1988;55:950-7.
12. Rose RJ. Genetic and environmental variance in content dimensions of the MMPI. J Pers Soc Psychol 1988;55:302-11.
13. Tellegen A, Lykken DT, Bouchard TJ, Wilcox KJ, Segal NL, Rich S. Personality similarity in twins reared apart and together. J Pers Soc Psychol 1988;54:1031-9.
14. Clark LA, Watson D. Tripartite model of anxiety and depression: psychometric evidence and taxonomic implications. J Abnorm Psychol 1991;100:316-36.
15. Clark LA, Watson D, Mineka S. Temperament, personality, and the mood and anxiety disorders. J Abnorm Psychol 1994;103:103-16.
16. Kendler KS, Neale MC, Kessler RC, Heath AC, Eaves LJ. A longitudinal twin study of personality and major depression in women. Arch Gen Psychiatry 1993;50:853-62.
17. Stahl SM. Mixed anxiety and depression: clinical implications. J Clin Psychiatry 1993;54(1 Suppl):33S-8S.
18. Preskorn SH, Fast GA. Beyond signs and symptoms: the case against a mixed anxiety and depression category. J Clin Psychiatry 1993;54(1 Suppl):24S-32S.
19. Joffe R, Sokolov S, Streiner D. Antidepressant treatment of depression: a meta-analysis. Can J Psychiatry 1996;41:613-6.
20. Anderson IM, Tomenson BM. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 1994;8:238-42.
21. Kasper S, Fuger J, Moller HJ. Comparative efficacy of antidepressants. Drugs 1992;43:11-23.
22. Schatzberg AF, Cole JO. Benzodiazepines in depressive disorders. Arch Gen Psychiatry 1978;35:1359-65.
23. Petty F, Trivedi MH, Fulton M, Rush AJ. Benzodiazepines as antidepressants: does GABA play a role in depression? Biol Psychiatry 1995;38:578-91.
24. Jonas JM, Cohen MS. A comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic and depression: a review of the literature. J Clin Psychiatry 1993;54(10 Suppl):25S-45S.
25. Birkenhäger TK, Moleman P, Nolen WA. Benzodiazepines for depression? A review of the literature. Int Clin Psychopharmacolog 1995;10:181-95.
26. Cole JO, Kando JC. Adverse behavioral events reported in patients taking alprazolam and other benzodiazepines.J Clin Psychiatry 1993;54(10 Suppl):49S-61S.
27. Feighner JP, Aden GC, Fabre LF, Rickels K, Smith WT. Comparison of alprazolam, imipramine and placebo in the treatment of depression. JAMA 1983;249:3057-64.
28. Feighner JP, Meredith CH, Frost NR, Chammas S, Hendrickson G. A double-blind comparison of alprazolam vs imipramine and placebo in the treatment of major depressive disorder. Acta Psychiatr Scand 1983;68:223-33.
29. Rickels K, Feighner JP, Smith WT. Alprazolam, amitriptyline, doxepin and placebo in the treatment of depression. Arch Gen Psychiatry 1985;42:134-41.
30. Imlah NW. An evaluation of alprazolam in treatment of reactive or neurotic (secondary) depression. Br J Psychiatry 1985;146:515-9.
31. Mendels J, Senless AP. Comparative efficacy of alprazolam, imipramine, and placebo administered once a day in treating depressed patients. J Clin Psychiatry 1986;47:357-61.
32. Rickels K, Chung HR, Csanalosi IB, Hurowitz AM, London J, Wiseman K, and others. Alprazolam, diazepam, imipramine and placebo in outpatients with major depression. Arch Gen Psychiatry 1987;44:862-6.
33. Fabre LF, McLendon DM. A double-blind study comparing the efficacy and safety of alprazolam with imipramine and placebo in primary depression. Current Therapeutic Research 1980;27:474-82.
34. Laakman G, Faltermaier-Temizel M, Bossert-Zaudig S, Baghai T, Lorkowski T. Treatment of depressive outpatients with lorazepam, alprazolam, amitriptyline, and placebo. Psychopharmacology 1995;120:109-15.
35. Borison RL, Sinha D, Albrecht JW, Geber S, Diamond BI. Double-blind comparison of 3- and 6-mg fixed doses of alprazolam vs placebo in outpatients with major depressive disorder. Psychopharmacol Bull 1989;45(2):186-9.
36. Rickels K, Cohen D, Csanalosi IB, Harris H, Koepke H, Werblowsky J. Alprazolam and imipramine in depressed outpatients: a controlled study. Current Therapeutic Research 1982;42(6):157-64.
37. Remick RA, Keller FD, Buchanan RA, Gison RE, Fleming JAE. A comparison of the efficacy and safety and alprazolam and desipramine in depressed outpatients. Can J Psychiatry 1988;33:590-4.
38. Ansseau M, Ansoms C, Beckers G, Bogaerts M, Botte L, De Buck R, and others. Double-blind clinical study comparing alprazolam and doxepin in primary unipolar depression. J Affect Dis 1984;7:287-96.
39. Singh AN, Nair NPV, Suranyi-Cadotte B, Svhwartz G, Lizondo E. A double blind comparison of alprazolam and amitriptyline hydrochloride in the treatment of nonpsychotic depression. Can J Psychiatry 1988;33:218-22.
40. Remick RA, Fleming JAE, Buchanan RA, Keller FD, Hamilton P, Loomer F, and others. A comparison of the safety and efficacy of alprazolam and desipramine in moderately severe depression. Can J Psychiatry 1985;30:597-601.
41. Hubain PP, Castro P, Mesters P, de Martelaer V, Mendlewicz J. Alprazolam and amitriptyline in the treatment of major depressive disorder: a double-blind clinical and sleep EEG study. J Affect Disord 1990;18:67-73.
42. Fawcett J, Edwards JH, Kravitz HM, Jeffries H. Alprazolam: an antidepressant? Alprazolam, desipramine, and an alprazolam-desipramine combination in the treatment of adult depressed outpatients. J Clin Psychopharmacol 1987;7:295-310.
43. Overall JE, Biggs J, Jacobs M, Holden K. Comparison of alprazolam and imipramine for the treatment of outpatient depression. J Clin Psychiatry 1987;48:15-9.
44. Goldberg SC, Ettigi P, Schulz PM, Hamer RM, Hayes PE, Friedel RO. Alprazolam vs imipramine in depressed outpatients with neurovegetative signs. J Affect Disord 1986;11:139-45.
45. Eriksson B, Nagy A, Sarmark JE, Thelander U. Alprazolam compared to amitripryline in the treatment of major depression. Acta Psychiatr Scand 1987;75:656-63.
46. Rush AJ, Erman MK, Schlesser MA, Roffwarg HP, Vasavada N, Khatarni M, and others. Alprazolam vs amitriptyline in depressions with reduced REM lacticies. Arch Gen Psychiatry 1985;42:1154-9.
47. Lapierre YD, Browne M, Oyewumi K, Sarantidis D. Alprazolam and amitriptyline in the treatment of moderate depression. Int Clin Psychopharmacol 1994;9:41-5.
48. Gibbons RD, Clark DC, Kupfer DJ. Exactly what does the Hamilton Depression Rating Scale measure? J Psychiatr Res 1993;27(3):259-73.
49. Maier W, Philipp M, Gerken A. Dimensions of the Hamilton Depression Scale. European Archives of Psychiatry and Neurological Sciences 1985;234:417-22.
50. Rehm LP, O'Hara MW. Item characteristics of the Hamilton Rating Scale for Depression, J Psychiatr Res 1985;19:31-41.
51. Cutler NR, Sramek JJ, Keppel Hesselink JM, Krol A, Roeschen J, Rickels K, and others. A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial. J Clin Psychopharmacol 1993;13:429-37.
52. 1A agonists in anxiety and depression. J Psychopharmacol 1993;7(3):283-9.
53. Sussman N. The uses of buspirone in psychiatry. J Clin Psychiatry Monograph 1994;12:3-19.
54. Eison MS. The new generation of serotonergic anxiolytics: possible clinical roles. Psychopathology 1989;22(1 Suppl):13S-20S.
55. Fabre LF. Buspirone in the management of major depression: a placebo-controlled comparison. J Clin Psychiatry 1990;51(9 Suppl):55S-61S.
56. Rickels K, Amsterdam JD, Clary C, Puzzuoli G, Schweizer E. Buspirone in major depression: a controlled study. J Clin Psychiatry 1991;52:34-8.
57. 1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol 1990;10(3 Suppl):67S-76S.
58. Heller AH, Beneke M, Kuemmel B, Spencer D, Kurtz NM. Ipsapirone: evidence for efficacy in depression. Psychopharmacol Bull 1990;26:219-22.
59. Jenkins SW, Robinson DS, Fabre LF, Andary JJ, Messina ME, Reich LA. Gepirone in the treatment of major depression. J Clin Psychopharmacol 1990;10(3 Suppl):77S-85S.
60. Brawman-Mintzer O, Lydiard RB. Generalized anxiety disorder: issues in epidemiology. J Clin Psychiatry 1996;57(7 Suppl):3S-8S.
61. Schweizer E, Rickels K. The long-term management of generalized anxiety disorder: issues and dilemmas. J Clin Psychiatry 1996;57(7 Suppl):9S-12S.
62. Massion AO, Warshaw MG, Keller MB. Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder. Am J Psychiatry 1993;150:600-607.
63. Roy-Byrne PP. Generalized anxiety and mixed anxiety-depression: association with disability and health care utilization. J Clin Psychiatry 1996;57(7 Suppl):86S-91S.
64. Rickels K, Case WG, Downing RW, Winokur A. Long-term diazepam therapy and clinical outcome. JAMA 1983;250:767-71.
65. Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med 1993;328:1398-405.
66. Rickels K. Buspirone in clinical practice. J Clin Psychiatry 1990;51(9 Suppl):51S-4S.
67. Liebowitz MR, Fyer AJ, Gorman JM, Campeas RB, Sandberg DP, Hollander E, and others. Tricyclic therapy of the DSM-III anxiety disorders: a review with implications for further research. J Psychiatr Res 1988;22(1 Suppl):7S-31S.
68. Kahn RJ, McNair DN, Lipman RS, Covi L, Rickels K, Downing R, and others. Imipramine and chlordiazepoxide in depressive and anxiety disorders II. Efficacy in anxious outpatients. Arch Gen Psychiatry 1986;43:79-85.
69. Klein DF. False suffocation alarms, spontaneous panics, and related conditions: an integrative hypothesis. Arch Gen Psychiatry 1993;50:306-17.
70. Klein DF. Panic disorder and agoraphobia: hypothesis hothouse. J Clin Psychiatry 1996;57(6 Suppl):21S-27S.
71. Hoehn-Saric R, McLeod DR, Zimmerli WD. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry 1988;49:293-301.
72. Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone and diazepam. Arch Gen Psychiatry 1993;50:884-95.
73. Rocca P, Fonzo V, Scotta M, Zanalda E, Ravizza L. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand 1997;95:444-50.
74. Liebowitz MR, Hollander E, Schneier F. Anxiety and depression: discrete diagnostic entities? J Clin Psychopharmacol 1990;10(3 Suppl):61S-66S.
75. Hollander E, Cohen LJ. The assessment and treatment of refractory anxiety. J Clin Psychiatry 1994;55(2 Suppl):27S-31S.
76. Garvey MJ, Cook B, Noyes R. The occurrence of a prodrome of generalized anxiety in panic disorder. Compr Psychiatry 1988;29:445-9.
77. Nisita C, Petracca A, Akiskal HS, Galli L, Gepponi I, Cassano GB. Delimitation of generalized anxiety disorder: clinical comparisons with panic and major depressive disorders. Compr Psychiatry 1990;31:409-15.
78. Brown TA, Barlow DH, Leibowitz MR. The empirical basis of generalized anxiety disorder. Am J Psychiatry 1994;151:1272-80.
79. Kendler KS, Neale MC, Kessler RC, Heath AC, Eaves LJ. Major depression and generalized anxiety disorder: same genes, (partly) different environments? Arch Gen Psychiatry 1992;49:716-22.
80. Roy MA, Neale MC, Pedersen NL, Mathé A, Kendler KS. A twin study of generalized anxiety disorder and major depression. Psychol Med 1995;25:1037-49.
81. Reich J. Family psychiatric histories in male patients with generalized anxiety disorder and major depressive disorder. Ann Clin Psychiatry 1995;7:71-8.
82. Kendler KS. Major depression and generalized anxiety disorder: same genes, (partly) different environments - revisited. Br J Psychiatry 1996;168(30 Suppl):68S-75S.
83. Kendler KS, Walters EE, Neale MC, Kessler RC, Heath AC, Eaves LJ. The structure of the generic and environmental risk factors for six major psychiatric disorders in women. Arch Gen Psychiatry 1995;52:374-83.
84. Tiller JWG, Biddle N, Maguire KP, Davies BM. The dexamethasone suppression test and plasma dexamethasone in generalized anxiety disorder. Biol Psychiatry 1988;23;261-70.
85. Butler PD, Nemeroff CB. Corticotropin-releasing factor as a possible cause of comorbidity in anxiety and depressive disorders. In: Maser JD, Cloninger RC, editors. Comorbidity of mood and anxiety disorders. Washington (DC): American Psychiatric Press; 1990. pp 413-35.
86. Abelson JL, Glitz D, Cameron OG, Lee MA, Bronzo M, Curtis GC. Blunted growth hormone response to clomdine in patients with generalized anxiety disorder. Arch Gen Psychiatry 1991;48:157-62.
87. Copp JE, Schwiderski UE, Robinson DS. Symptom comorbidity in anxiety and depressive disorders. J Clin Psychopharmacol 1990;10(3 Suppl):52S-60S.
88. Riskind JH, Beck AT, Brown G, Steer RA. Validity of reconstructed Hamilton Scales. J Nerv Ment Dis 1987;175:474-9.
89. Wittchen HU, Zhao S, Kessler RC, Eaves WW. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:355-64.
90. Clark DA, Steer RA, Beck AT. Common and specific dimensions of self-reported anxiety and depression: implications for the cognitive and tripartite models. J Abnorm Psychol 1994;103:645-54.
91. Clark DA, Beck AT, Beck JS. Symptom differences in major depression, dysthymia, panic disorder, and generalized anxiety disorder. Am J Psychiatry 1994;151:205-9.
92. Boulenger JP, Lavallée YJ. Mixed anxiety and depression: diagnostic issues. J Clin Psychiatry 1993;54(1 Suppl):3S-8S.
93. Eison MS. Serotonin: a common neurobiologic substrate in anxiety and depression. J Clin Psychopharmacol 1990;10(3 Suppl):26S-30S.